Firstly, if you are interested in OTC stocks like Hikma Pharmaceutical, you will be doing yourself a massive favor by joining the Trader HR chat room (the people there are experts at tricky stocks like this), so do that now – we also strongly recommend Microcap Millionaires where you can learn how to profit hugely off lesser known OTC stocks (what you find there is much more interesting than HKMPF, in our view). These recommendations are current as of 2019-10-18. Now onto the news and analysis.
REPORTING FOR 2019-10-18 | BUNDESPREMIERLEAGUE.COM: We have conducted a deep analysis of how Hikma Pharmaceutical (HKMPF) has been trading over the last 2 weeks and the past day especially. On its latest session, Hikma Pharmaceutical (HKMPF) opened at 25.4, reaching a high of 25.4 and a low of 25.4 before closing at a price of 25.4. There was a total volume of 600.0.
VOLUME INDICATORS: We saw an accumulation-distribution index of 24.05, an on-balance volume of -25.02, chaikin money flow of 0.04695 and a force index of 0.1444. There was an ease of movement rating of 0.00013, a volume-price trend of 1.97387 and a negative volume index of 1000.0.
VOLATILITY: We noted an average true range of 0.1304, bolinger bands of 25.4, an upper bollinger band of 25.4, lower bollinger band of 25.4, a bollinger high band indicator of nan, bollinger low band indicator of 1.0, a central keltner channel of 25.4, high band keltner channel of 25.4, low band keltner channel of 25.4, a high band keltner channel indicator of 1.0 and a low band keltner channel indicator of 1.0. There was a donchian channel high band of 25.4, a donchian channel low band of 25.4, a donchian channel high band indicator of 1.0, and a donchian channel low band indicator of 1.0.
TREND: We calculated a Moving Average Convergence Divergence (MACD) of -0.01512, a MACD signal of -0.0045, a MACD difference of -0.01062, a fast Exponential Moving Average (EMA) indicator of 25.4, a slow Exponential Moving Average (EMA) indicator of 25.4, an Average Directional Movement Index (ADX) of unknown, an ADX positive of 20.0, an ADX negative of 20.0, a positive Vortex Indicator (VI) of 1.0, a negative VI of 1.0, a trend vortex difference of 0.0032, a trix of 4.74937, a Mass Index (MI) of 4.98111, a Commodity Channel Index (CCI) of -166.66667, a Detrended Price Oscillator (DPO) of -1.83028, a KST Oscillator (KST) of 77.65387 and a KST Oscillator (KST Signal) of 77.65387 (leaving a KST difference of -2.57958). We also found an Ichimoku rating of 25.4, an Ichimoku B rating of 25.4, a Ichimoku visual trend A of 23.83291, an Ichimoku visual trend B of 24.50826, an Aroon Indicator (AI) up of 4.0 and an AI indicator down of 4.0. That left a difference of -16.0.
MOMENTUM: We found a Relative Strength Index (RSI) of 50.0, a Money Flow Index (MFI) of 100.0, a True Strength Index (TSI) of 100.0, an ultimate oscillator of 100.0, a stochastic oscillator of 50.0, a stochastic oscillator signal of 50.0, a Williams %R rating of -50.0 and an awesome oscillator of -0.02533.
RETURNS: There was a daily return of 7.76539, a daily log return of -1.50737 and a cumulative return of -1.49606.
What the heck does all of this mean? If you are new to technical analysis, the above may be gibberish to you, and that’s OK (though we do advise learning these things). The bottom line is that AS OF 2019-10-18 (if you are reading this later, the analysis will be out of date), our analysis of technical indicators for Hikma Pharmaceutical (HKMPF) is telling us that this is potentially a buy. Please comment if you disagree with this conclusion or if you find any errors in the analysis above.
For a more complete analysis, run all of this through the BTMA software. Also, to stay up to date with what is happening on Hikma Pharmaceutical, we strongly advise Hikma Pharmaceutical investors to subscribe to MarketBeat.com’s daily email newsletter for updates, news and analyst ratings on Hikma Pharmaceutical and any other stocks you want – without this you are trading blind:
DISCLAIMER: We are not registered investment advisers and the above analysis should be taken at face value only. We strongly advise against buying or selling Hikma Pharmaceutical (HKMPF) based solely on our analysis above, and are not responsible for any losses that you may incur if you choose make any investment decisions based on the above.
I am the driving force behind BPL and a professional daytrader. I will be providing technical analysis of various stocks on BPL.
Latest posts by Anthony Rankin (see all)
- New Things To Consider With Amtrust Financial Services Inc Pfd. A (OTCMKTS:AFSIA) (2019-11-21) - November 21, 2019
- A Recap Of Kansas City Life Insurance Company (OTCMKTS:KCLI) (2019-11-21) - November 21, 2019
- What Mimedx Group Inc (OTCMKTS:MDXG) Just Did (2019-11-21) - November 21, 2019